Abstract
Endoplasmic reticulum (ER) has evolved an adaptive mechanism called unfolded protein response (UPR) at the initial stage to restore cellular homeostasis. The three ER transmembrane sensors, such as IRE1α, PERK, and ATF6, are the key factors to decide cell fates. They exhibit both advantageous and disadvantageous effects, depending on the micro-environmental state of cells. ER stress has been implicated in chondrocytes proliferation, differentiation, and hypertrophy through regulating transcriptional factors SOX9, Ihh, BMP-2, RUNX, and HIF1/2α. In addition, the chronic ER stress induced by the mutant proteins becomes the pathophysiology of chondrodysplasia. On the other hand, ER stress may induce chondrocytes apoptosis, leading to the degeneration of cartilage. eIF2α-CHOP and JNK activation are the remarkably apoptotic responses to ER stress, while XBP1s and Bip exhibit pro-survival effects. These factors might potentially become therapeutic targets for joint diseases management. This article reviews the pro-survival and pro-apoptotic effects of ER stress as well as their implications in cartilage and chondrocytes.
Keywords: ER stress, UPR, chondrocytes, IRE1α-XBP1/IRE1α-RIDD, PERK- eIF2α, CHOP.
Current Pharmaceutical Design
Title:The Roles of Endoplasmic Reticulum Stress in the Pathophysiological Development of Cartilage and Chondrocytes
Volume: 23 Issue: 11
Author(s): Xiaoliang Yuan, Haiqing Liu, Linfu Li, Hai Liu, Jianqiong Yang, Weimei Shi, Yuan Feng, Hao Huang*Longhuo Wu*
Affiliation:
- College of Pharmacy, Gannan Medical University, Ganzhou 341000,China
- College of Pharmacy, Gannan Medical University, Ganzhou 341000,China
Keywords: ER stress, UPR, chondrocytes, IRE1α-XBP1/IRE1α-RIDD, PERK- eIF2α, CHOP.
Abstract: Endoplasmic reticulum (ER) has evolved an adaptive mechanism called unfolded protein response (UPR) at the initial stage to restore cellular homeostasis. The three ER transmembrane sensors, such as IRE1α, PERK, and ATF6, are the key factors to decide cell fates. They exhibit both advantageous and disadvantageous effects, depending on the micro-environmental state of cells. ER stress has been implicated in chondrocytes proliferation, differentiation, and hypertrophy through regulating transcriptional factors SOX9, Ihh, BMP-2, RUNX, and HIF1/2α. In addition, the chronic ER stress induced by the mutant proteins becomes the pathophysiology of chondrodysplasia. On the other hand, ER stress may induce chondrocytes apoptosis, leading to the degeneration of cartilage. eIF2α-CHOP and JNK activation are the remarkably apoptotic responses to ER stress, while XBP1s and Bip exhibit pro-survival effects. These factors might potentially become therapeutic targets for joint diseases management. This article reviews the pro-survival and pro-apoptotic effects of ER stress as well as their implications in cartilage and chondrocytes.
Export Options
About this article
Cite this article as:
Yuan Xiaoliang, Liu Haiqing, Li Linfu, Liu Hai, Yang Jianqiong, Shi Weimei, Feng Yuan , Huang Hao *, Wu Longhuo*, The Roles of Endoplasmic Reticulum Stress in the Pathophysiological Development of Cartilage and Chondrocytes, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612822666161025152423
DOI https://dx.doi.org/10.2174/1381612822666161025152423 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry One Hundred Faces of Cyclopamine
Current Pharmaceutical Design EXTraordinary Bones: Functional and Genetic Analysis of the EXT Gene Family
Current Genomics The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Diquaternized Curarelike Myorelaxants: Structure and Biological Activity
Mini-Reviews in Medicinal Chemistry Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Cells Under Pressure – Treatment of Eukaryotic Cells with High Hydrostatic Pressure, from Physiologic Aspects to Pressure Induced Cell Death
Current Medicinal Chemistry Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry